- Home
- MYGN vs CTKB Comparison
MYGN vs CTKB Comparison
Compare MYGN & CTKB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MYGN
- CTKB
- Stock Information
- Founded
- MYGN 1991
- CTKB 1990
- Country
- MYGN United States
- CTKB United States
- Employees
- MYGN N/A
- CTKB N/A
- Industry
- MYGN Biotechnology: In Vitro & In Vivo Diagnostic Substances
- CTKB Biotechnology: Electromedical & Electrotherapeutic Apparatus
- Sector
- MYGN Health Care
- CTKB Health Care
- Exchange
- MYGN Nasdaq
- CTKB Nasdaq
- Market Cap
- MYGN 423.1M
- CTKB 430.6M
- IPO Year
- MYGN 1995
- CTKB 2021
- Fundamental
- Price
- MYGN $3.91
- CTKB $3.64
- Analyst Decision
- MYGN Hold
- CTKB Hold
- Analyst Count
- MYGN 15
- CTKB 4
- Target Price
- MYGN $15.14
- CTKB $6.00
- AVG Volume (30 Days)
- MYGN 1.3M
- CTKB 953.6K
- Earning Date
- MYGN 08-12-2025
- CTKB 08-06-2025
- Dividend Yield
- MYGN N/A
- CTKB N/A
- EPS Growth
- MYGN N/A
- CTKB N/A
- EPS
- MYGN N/A
- CTKB N/A
- Revenue
- MYGN $831,300,000.00
- CTKB $197,050,000.00
- Revenue This Year
- MYGN N/A
- CTKB $0.74
- Revenue Next Year
- MYGN $6.64
- CTKB $7.85
- P/E Ratio
- MYGN N/A
- CTKB N/A
- Revenue Growth
- MYGN 7.38
- CTKB N/A
- 52 Week Low
- MYGN $3.78
- CTKB $2.37
- 52 Week High
- MYGN $29.30
- CTKB $7.63
- Technical
- Relative Strength Index (RSI)
- MYGN 30.48
- CTKB 57.63
- Support Level
- MYGN $4.43
- CTKB $3.20
- Resistance Level
- MYGN $4.83
- CTKB $3.44
- Average True Range (ATR)
- MYGN 0.25
- CTKB 0.18
- MACD
- MYGN -0.10
- CTKB 0.03
- Stochastic Oscillator
- MYGN 9.32
- CTKB 79.71
About MYGN Myriad Genetics Inc.
Myriad Genetics Inc is a molecular diagnostics company that provides testing services designed to assess an individual's risk of developing a disease. The firm produces MyRisk, a 48-gene panel capable of identifying the elevated risk of developing 11 types of cancer. Other diagnostic products include BRACAnalysis CDx, the FDA-approved companion diagnostic for PARP inhibitors; GeneSight, which helps improve responses to psychotropic drugs for patients suffering from depression; and Prequel, a noninvasive prenatal test. Precise Oncology Solutions, launched in 2022, combines Precise Tumor with companion diagnostic and prognostic tests such as MyChoice CDx, Prolaris, and EndoPredict. The firm also offers pharma and biotech companies biomarker discovery and companion diagnostic services.
About CTKB Cytek Biosciences Inc.
Cytek Biosciences Inc is a cell analysis solutions company advancing the next generation of cell analysis tools by leveraging novel technical approaches. Its core instruments, the Cytek Aurora and Northern Lights systems, are the first full-spectrum flow cytometers able to deliver high-resolution, high-content, and high-sensitivity cell analysis by utilizing the full spectrum of fluorescence signatures from multiple lasers to distinguish fluorescent tags on single cells. Its FSP platform addresses the inherent limitations of other technologies by providing a higher density of information with greater sensitivity, more flexibility, and increased efficiency, all at a lower cost for performance. Geographically, the company generates a majority of its revenue from the United States.